Lung Cancer: Real-world studies to evaluate the efficacy of immunotherapy in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

For metastatic non-small cell lung cancer ( NSCLC ) with negative EGFR and ALK mutations , single-agent immunotherapy or combined chemotherapy is currently recommended as the first-line treatment

For metastatic non-small cell lung cancer ( NSCLC ) with negative EGFR and ALK mutations , single-agent immunotherapy or combined chemotherapy is currently recommended as the first-line treatment

Study inclusion criteria: NSCLC patients aged ≥18 years, stage III-IV, received first-line immune monotherapy or immune-combined chemotherapy

Study inclusion criteria: NSCLC patients aged ≥18 years, stage III-IV, received first-line immune monotherapy or immune-combined chemotherapy

Research Overview

Of the 4271 patients who received IO combined chemotherapy, 814 (19%) were squamous cell carcinoma and 3457 (81%) were non-squamous cell carcinoma

Of the 4271 patients who received IO combined chemotherapy, 814 (19%) were squamous cell carcinoma and 3457 (81%) were non-squamous cell carcinoma

Evaluation of the efficacy of IO combined with chemotherapy

There were 3041 patients receiving single-agent immunotherapy, of which 875 (29%) were squamous cell carcinoma and 2,166 (71%) were non-squamous cell carcinoma

There were 3041 patients receiving single-agent immunotherapy, of which 875 (29%) were squamous cell carcinoma and 2,166 (71%) were non-squamous carcinoma

 Evaluation of the efficacy of IO monotherapy

In summary, real-world studies have evaluated that the survival of patients with advanced non-small cell lung cancer (NSCLC) treated by immunotherapy is lower than that in clinical studies, indicating that further improvements in treatment are needed

In summary, real-world studies have evaluated that the survival of patients with advanced non-small cell lung cancer (NSCLC) treated by immunotherapy is lower than that in clinical studies, indicating that further improvements in treatment are needed

Original source:

Waterhouse D, Lam J, Betts KA, et al.

Waterhouse D, Lam J, Betts KA, et al.
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Lung Cancer.
2021 Jun;156:41-49.
doi: 10.
1016/j .
lungcan.
2021.
04.
007.
Epub 2021 Apr 14.
PMID: 33894493.


Leave a message here